Our peptide drug product platform offers a comprehensive formulation service for oral solid and injectable dosage forms. The formulation team is supported by more than a thousand of scientists and state-of-the-art facilities at our integrated drug product R&D and manufacturing facilities in Wuxi city, Shanghai Waigaoqiao site in China. Both two sites are within 2-hour drive to our peptide API site in Changzhou, providing an integrated peptide API and formulation development and manufacturing solution.
Our oral solid platform provides a variety of dosage forms including tablets, capsules, powder, granules, liquid in bottle, liquid filled hard capsules and softgels with billions of doses annual capacity. In 2022, the team evaluated 2,498 molecules in preformulation studies, delivered 2,815+ clinical batches and worked on 45+ late phase and commercial projects
Our injectable platform provide formulation development and manufacturing for solution, emulsion, lyophilized powder and liposome in vial, pre-filled syringe and cartridge. Currently, we have the injectable production capacity of 32 million units per year, which will be expanded to 42 million unit in 2024.
Do you have peptide drug candidates in development? Attend our webinar co-presented by Yen-Huei Lin, Ph.D. Exec. Director,
Biopharmaceutical Development and Manufacturing at Neuraly and William Fang, Head of Oligo/Peptide Business at WuXi STA about how an integrated CMC partnership was critical in accelerating a novel peptide to phase 1 clinical trial.